Finance

Roche has no plans for job cuts and business is healthy, CEO says

Published by Global Banking & Finance Review

Posted on December 29, 2024

2 min read

· Last updated: January 27, 2026

Add as preferred source on Google
Roche CEO Thomas Schinecker discusses company's healthy business outlook - Global Banking & Finance Review
A portrait of Roche CEO Thomas Schinecker emphasizing the company's stable workforce and healthy business amidst market challenges. This image illustrates Roche's commitment to growth and innovation in the finance sector.
Global Banking & Finance Awards 2026 — Call for Entries

ZURICH (Reuters) - Swiss pharmaceutical company Roche is not planning job cuts and its business is healthy, CEO Thomas Schinecker was quoted as saying by a Swiss newspaper on Sunday. Roche's share

Roche CEO: Business Healthy, No Plans for Job Cuts

ZURICH (Reuters) - Swiss pharmaceutical company Roche is not planning job cuts and its business is healthy, CEO Thomas Schinecker was quoted as saying by a Swiss newspaper on Sunday.

Roche's share price has fallen far below peaks it scaled in April 2022 and the CEO was questioned about the company's staffing plans in the context of recent setbacks in its development of drugs to treat cancer, among other illnesses.

"The number of workers is constant to slightly increasing," Schinecker told the NZZ am Sonntag in an interview when asked if the company was planning layoffs.

"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he said, while noting that Roche's budget for research and development was stable and not growing.

Asked when Roche's planned anti-obesity drug would hit the market, Schinecker said it could be around 2029 or sooner.

Addressing the outlook more broadly for next year, particularly in light of the German economy's recent struggles, the Roche CEO said Europe still faced challenges.

"There's some economic growth in the United States, but things are more difficult in China at the moment," he said. "And in Europe it will take some time before we get out of this."

(Writing by Dave Graham; Editing by David Holmes)

Key Takeaways

  • Roche CEO confirms no job cuts planned.
  • Business remains healthy despite share price drop.
  • R&D budget is stable, not increasing.
  • Anti-obesity drug expected by 2029.
  • Challenges persist in Europe and China.

Frequently Asked Questions

What is the main topic?
The main topic is Roche's business health and staffing plans as confirmed by CEO Thomas Schinecker.
Is Roche planning any job cuts?
No, Roche CEO Thomas Schinecker confirmed that there are no plans for job cuts.
What is the outlook for Roche's anti-obesity drug?
Roche's anti-obesity drug is expected to hit the market by 2029 or sooner.

Related Articles

More from Finance

Explore more articles in the Finance category